Ralliant (NYSE:RAL) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Ralliant (NYSE:RAL) from a hold rating to a buy rating in a report issued on Saturday morning.

Several other analysts have also recently weighed in on RAL. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Evercore assumed coverage on Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price objective for the company. Barclays upped their price objective on shares of Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada raised their target price on shares of Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research note on Thursday. Finally, Citigroup lifted their target price on shares of Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $70.80.

Ralliant Trading Up 4.6%

Ralliant stock opened at $70.01 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41. The stock has a market cap of $7.84 billion and a P/E ratio of -6.40. The firm’s fifty day moving average price is $65.21 and its 200-day moving average price is $53.13.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million during the quarter. Ralliant’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Ralliant will post 2.64 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Investors of record on Monday, June 8th were given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio (DPR) is presently -1.83%.

Institutional Trading of Ralliant

Several institutional investors have recently added to or reduced their stakes in the business. Danske Bank A S purchased a new position in shares of Ralliant in the fourth quarter worth about $25,000. V Square Quantitative Management LLC bought a new stake in shares of Ralliant in the 4th quarter valued at about $26,000. Allworth Financial LP boosted its holdings in Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after acquiring an additional 293 shares during the period. Palisade Asset Management LLC purchased a new stake in Ralliant during the 3rd quarter valued at about $26,000. Finally, BOKF NA bought a new position in Ralliant during the 3rd quarter worth approximately $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.